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ABSTRACT 
Increased binding sites for “peripheral-type” benzodiazepine receptor (PTBR) ligands 
have been described in a wide range of neurological disorders including both human and 
exper-imental epilepsy. This study was undertaken to assess PTBR expression in relation 
to the presence of hippocampal sclerosis in human temporal lobe epilepsy (TLE). For this 
pur-pose, hippocampal CA1 subfields were dissected from surgical samples from patients 
with therapy-refractive TLE with (n D 5) or without (n D 2) hippocampal sclerosis and 
from age-matched nonepileptic postmortem controls (n D 5). PTBR expression was 
assessed by immunohistochemistry and reverse-transcription polymerase chain reaction. 
Receptor sites were evaluated using an in vitro binding assay and the selective PTBR 
ligand [3H]PK11195. Epileptic patients with hippocampal sclerosis showed increases in 
PTBR binding sites, im-munoreactivity, and mRNA expression compared to both 
nonsclerotic TLE patients and postmortem nonepileptic controls. Induction of PTBR 
expression and binding sites were directly correlated with the presence of hippocampal 
sclerosis and the accompanying reac-tive gliosis. 
Key words: Temporal lobe epilepsy; hippocampus; peripheral-type benzodiazepine receptors; 
position emission tomography; astrocytes. 
INTRODUCTION 
The “peripheral-type” benzodiazepine receptor (PTBR) is a multimeric complex found 
mainly on the outer mitochondrial membrane of astrocytes (Anholt et al., 1986; Basile 
and Skolnick, 1986). PTBR may also be colocalized with activated microglia in injured 
brain tissue (Kuhlmann and Guilarte, 2000). PTBR is composed of three subunits, an 18 
KDa iso-quinoline carboxamide-binding protein (IBP), a 34 KDa voltage-dependent anion 
channel, and a 30 KDa adenine nucleotide carrier. PTBR has been implicated in various 
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functions, such as steroidogenesis, respiration, cell growth, and differentiation, and in 
response to stress. PTBR expression is increased following brain injury and this increase 
in PTBR has been used as an indication of neuronal damage or loss in several 
neurodegenerative disorders, such as Alzheimer’s disease (Diorio et al., 1991), 
Huntington’s disease (Messmer and Reynolds, 1998), Wernicke’s encephalopathy 
(Desjardins et al., 1999), multiple sclerosis (Banati et al., 2000), and stroke-induced brain 
injury (Raghavendra Rao et al., 2000; Stephenson et al., 1995). Increased PTBR 
expression in these conditions has been associated with both microglial activation and 
reactive astrogliosis. 
An association between alterations of PTBR and epilepsy has been proposed for some 
time. Epileptic patients manifest increased binding sites for PTBR ligands in blood 
mononuclear cells (Caldiroli et al., 1997; Ferrarese et al., 1996; Larkin et al., 1993) as well 
as in brain (Beaurain et al., 1994; Johnson et al., 1992). In addition, both EL (epileptic 
mice; Nakamoto et al., 1996), and kainate-induced epileptic rats (Benavides et al., 1987) 
show increased brain densities of PTBR sites. It was suggested that these increases in 
PTBR sites were either the consequence of the epileptogenic process per se or resulted 
from the gliosis accompanying neuronal cell loss in hippocampus of epileptic animals. 
The aim of this study was to measure PTBR expression in surgically excised samples of 
hippocampus from patients with temporal lobe epilepsy (TLE) with or without 
hippocampal sclerosis. PTBR binding sites were assessed by an in vitro binding technique 
utilizing the highly selective ligand [3H]PK11195. Increased PTBR expression was 
visualized using immunohistochemistry and PTBR gene expression was measured by 
semiquantitative reverse-transcription polymerase chain reaction (RT-PCR). 
MATERIALS AND METHODS 
Patients 
Patients with intractable epilepsy (n = 5) suffered from complex partial seizures and 
the epileptic focus was localized to the temporal lobe in all patients as revealed by 
physical examination, magnetic resonance imaging, and long-term video monitoring. The 
hippocampus was removed surgically from these patients in order to achieve seizure 
control. Informed consent was obtained for all procedures. Hippocampal samples were 
rapidly frozen for molecular studies or immersion-fixed in phosphate-buffered saline 
(PBS) for neuropathological evaluation and subsequent correlative analysis. Epileptic 
patients with nonsclerotic hippocampus (n = 2), as well as postmortem hippocampus 
from neuropathologically con-firmed normal patients ( n = 5), were used as nonepileptic 
controls. CA1 region was microdissected from frozen samples according to the atlas of 
Paxinos and Watson (1986) and frozen at °80°C until RNA extraction. 
 
[3H]PK11195 Binding Assay 
Membrane suspensions were prepared as described previously (Rao and Butterworth, 
1997) with slight modifications. Briefly, each individual sample was homogenized in 100 
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volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.5), with 5 up-and-down strokes of the 
glass-Teflon pestle. The homogenates were centrifuged at 40,000 g for 20 min and the 
pellet was resuspended in the initial volume of buffer and stored as aliquots at °80°C. 
Membrane protein concentrations were determined by the methods of Lowry et al. 
(1951) using bovine serum albumin (Sigma) as standard. Experiments were performed in 
duplicate, membranes from postmortem controls and epileptic patients being used in 
parallel sets. To determine Bmax and Kd values, saturation binding experiments were 
performed. [3H]PK11195 was used at eight concentrations be-tween 0.1 and 7 nM. To 
examine the possible changes in receptor density, samples were incubated with 2 nM of 
[3H]PK11195. Aliquots of membrane suspension (400 L, 0.3– 0.6 mg/mL of protein) were 
incubated for 60 min at 4°C with [3H]PK11195 (specific activity 86 Ci/mmol) in a final 
volume of 500 L. Nonspecific binding was defined in the presence of 1 M unlabeled 
PK11195 (RBI). The incubation was stopped by dilution with ice-cold buffer, the samples 
were filtered under vacuum through Whatman GF/B filters using a Millipore harvester, 
and the filters were washed twice with 4 ml of ice-cold buffer. Filter-bound activity was 
extracted into 4.5 ml of Ultima-Gold (Packard), and then determined by liquid 
scintillation counting at 40% efficiency. Saturation binding data were analyzed by 
nonlinear curve fitting, using the program GraphPad Prism (GraphPad Software, Inc., San 
Diego, CA). With this program, values for Kd and Bmax are obtained by fitting curves to the 
data with the use of the equation Specific Binding D Bmax £ L=Kd C L , where Bmax is the 
maximum specific binding, L is the concentration of [3H]PK11195, and Kd is the 
dissociation constant. 
Immunohistochemistry 
Frozen sections (6 M) were fixed with methanol for 2 min at °20
±
C. The cell membranes 
were then permeabilized in PBS containing 1% Triton X-100 for 30 min at room 
temperature. The sections were rinsed with PBS and incubated with 0.3% H2O2 for 5 min 
to inactivate endogenous peroxidase. Nonspecific sites were blocked in PBS containing 
0.1% Triton X-100 (PBST) and 1.5% heat-inactivated goat serum for 30 min. Sections 
were incubated overnight at 4
±
C, with a mouse monoclonal antibody (1 g/mL) directed 
against human IBP (Sanofi Recherche, Montpellier, France) or HLA-DR, a human class II 
antigen of the major histocompatibility complex (PharMingen, NJ). After washing with 
PBST, sections were incubated with biotinylated goat antibody against mouse IgGs 
(Vector laboratory, CA) at a 1:200 dilution for 30 min at room temperature. Sections were 
washed with PBST and incubated with an avidin–biotin-peroxidase complex (Vectastain, 
Vector laboratory, CA) at a 1:500 dilution for 30 min. After washing with PBST, bound 
immunoglobulins were detected by incubation with 0.1 M Tris-HCl (pH 7.4) containing 
0.5 mg/mL 3,3-diaminobenzidine–HCl and 0.01% hydrogen peroxide. 
RNA Extraction 
Total RNA was extracted using TRI Reagent (MRC, Inc., Ohio) according to the 
manufacturer’s protocol. Putative contaminating DNA was eliminated by adding 100 U of 
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RNase-free DNase I per 50 mg of total RNA at 37°C for 1 h. Purified RNA was then 
extracted with phenol, precipitated with ethanol, and resuspended in 
diethylpyrocarbonate-treated water. RNA samples were kept at °70°C until use. 
RT-PCR Analysis 
Actin was used as an internal standard to monitor loading variations. Total RNA (0.5 mg) 
was mixed with 10 mM Tris-HCl (pH 8.3), 1.0 mM MgCl2, 50 mM KCl, 0.01% (w/v) bovine 
serum albumin, 100 mM dNTPs, primers at 1 mM each, AMV reverse transcriptase (80 
U/mL), Taq DNA polymerase (20 U/mL), and 50 mCi/mL [32P]dCTP (3000 Ci/mmol), for 
a total reaction volume of 50 mL. The reactions were initially car-ried out at 50°C for 15 
min, followed by PCR at 95°C for 30 s, at 62°C for 45 s, and at 72°C for 1 min. 
Amplification efficiency conditions were determined after a kinetic study, to ensure all 
experiments were performed within the exponential phase of amplification where PCR 
product remains proportional to initial template concentration (data not shown). Actin 
and PTBR (IBP subunit) were amplified for 18 and 33 cycles, respectively. After 
amplification, the samples were electrophoresed onto 9% polyacrylamide gels, dried, and 
autoradiographed at °70°C with an intensifying screen. Each band was excised and 
Cerenkov radiation was quantitated using a b-counter. Oligonucleotide primers were de-
signed using the PRIME program (Genetic Computer Group, Wisconsin) and synthesized 
by the Sheldon Biotechnology Center (McGill University, Quebec) based on the following 
GeneBank accession numbers: X00351 (b-Actin; Ponte et al., 1984) and L21951-L21954 
(PTBR; Lin et al., 1993). The forward and reverse primer sequences were as follows: 
GACCTGACTGACTACCTCAT and AGACAGCACTGTGTTGGCGT (b-actin, 350 bp); and 
GCCCTTCCCGGAGCGTGCC and CGGCGTACCAGCGGAGAC (PTBR, 164 bp). The specificity 
of the oligonucleotide primers was verified using the program BLASTN (National Center 
for Biotechnology Information, Bethesda, MD). 
Statistical Analysis 
Data are expressed as means ±SEM. A probability of less than 5% ( p < 0:05) was 
considered to indicate statistical significance. All statistical analyses were performed 
using the computer software GraphPad Prism. Statistical significance of differences 
between the groups was determined with the unpaired, two-tailed Student’s t test. 
RESULTS 
Saturation binding curves for the binding of the PTBR ligand [3H]PK11195 to crude 
synaptic membrane preparations from controls and from TLE patients obtained at sites 
was observed in TLE samples. Bmax and Kd values for TLE patients were 694 ± 61:7 
fmol/mg protein and 2:15 ± 0:5 nM, respectively. In comparison, Bmax and Kd values for 
controls were 282 ± 25:0 fmol/mg protein and 0:94 ± 0:29 nM, respectively. 
Hematoxylin-eosin staining of sections from TLE patients showed, in five of seven cases, 
an almost complete loss of neurons from the CA1 subfield (Fig. 2). In all five cases PTBR 
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immunolabeling studies revealed increased immunoreactivity confined to astrocytes in 
these sections (Fig. 2, panel d). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Increased density of binding sites for the PTBR ligand [3 H]PK11195 in TLE. (A) 
Non-linear regression curve. (B) The corresponding Rosenthal–Scatchard plot of 
3[H]PK11195 binding to the CA1 subfield of hippocampus in postmortem controls (o) and 
epileptic patients with hippocampal sclerosis ( ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Loss of CA1 hippocampal neurons results in astrocytic proliferation and 
increased PTBR immunoreactivity. Panel a: HCE staining of CA1 subfield from a normal 
control; Panel b: H CE staining of CA1 subfield from a patient with TLE and 
hipppocampal sclerosis. Note the neuronal cell loss throughout this field. Panels c and d: 
PTBR immunostaining. Note the lack of staining in control (Panel c) and the intense 
immunostaining in TLE patient (Panel d). 
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Figure 3. Upper panel: Expression of the PTBR mRNA in TLE patients. 
Total RNA was extracted from the hippocampal CA1 subfield of patients 
with (lanes 6–10) or without (lanes 3–4) hippocampal sclerosis. β-Actin 
(351 bp) and PTBR (164 bp) were amplified by RT-PCR for 18 and 33 
cycles, respectively. AMV reverse transcriptase was omitted (as a negative 
control) in lanes 2 and 5. Lower panel: PTBR expression normalized to 
percentage of actin expression in patients with TLE with hippocampal 
sclerosis (hs) versus patients without hippocampal sclerosis (non-hs). 
PTBR was significantly increased in the hs group compared to the non-hs 
group ( p < 0:01 by Student’s t test). 
At the mRNA level, TLE patients with hippocampal sclerosis showed significantly 
increased (by 66%, p < 0:01) PTBR expression compared to two patients with TLE who 
did not manifest hippocampal sclerosis (Fig. 3). 
There was no evidence for the appearance of activated microglia/macrophages in the TLE 
patient samples used in this study as visualized using HLA-DR immunoreactivity (data 
not shown). 
DISCUSSION 
Results of the present study reveal significant increases in densities of binding sites for 
the PTBR ligand [3H]PK11195 in dissected hippocampal CA1 subfields from five patients 
with TLE. In all cases, increased PTBR sites were associated with severe neuronal loss 
(hippocampal sclerosis) and reactive gliosis. These findings confirm and extend those of 
previous studies which observed increased PTBR sites in blood mononuclear cells 
(Caldiroli et al., 1997; Ferrarese et al., 1996; Laikin et al., 1993) and brain (Beaurain et al., 
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1994; Johnson et al., 1992). Novel findings in the present study are those of increased 
PTBR sites in material from TLE patients with hippocampal sclerosis compared to similar 
material from patients with no pathological evidence of hippocampal sclerosis. 
Immunohistochemical studies revealed increased PTBR immunolabeling in CA1 subfield 
of TLE patients with hippocampal sclerosis. Increased immunolabeling was particularly 
localized on astrocytic elements suggesting that the increased PTBR signal was the 
consequence of astrogliosis which accompanied neuronal cell loss in TLE. Similar findings 
of increased PTBR sites coincident with astrocytic proliferation in the presence of 
neuronal loss were previously reported in Alzheimer’s disease (Diorio et al., 1991) and 
Wernicke’s encephalopathy (Desjardins et al., 1999; Leong et al., 1996). On the other 
hand, other disorders, such as multiple sclerosis (Banati et al., 2000) and stroke-induced 
brain injury (Stephenson et al., 1995), have been de-scribed in which increased PTBR 
sites coincided with the appearance of activated microglia rather than astrocytes. As 
previously reported by others (Beaurain et al., 1994), there was no evidence for a role of 
activated microglia activation in the samples used in the present study, suggesting that 
the hippocampal sclerosis in these patients was relatively longstanding. 
Although unlikely (given the relatively low levels of expression of PTBR in nonscle-rotic 
TLE patients observed in the present study), there is conceivably a role for PTBR 
activation in the pathogenesis of the epileptic process per se. PTBR mediates the trans-
port of cholesterol across the mitochondrial membrane and subsequently plays a role in 
the synthesis of the so-called neurosteroids, some of which have agonistic properties at 
GABA-A and NMDA receptors (Compagnone and Mellon, 2000). Activation of PTBR could 
therefore result in an imbalance between excitatory and inhibitory systems in the CNS 
(Majewska et al., 1987; Wu et al., 1991). Alternatively, increased PTBR in TLE may 
represent an adaptive phenomenon in hippocampal fields aimed at increasing neuroinhi-
bition via the synthesis of epalons, a class of neurosteroids with anticonvulsant 
properties shown previously to allosterically potentiate the effect of GABA on chloride 
conductance by the GABA-A receptor complex (Gee et al., 1995). 
Findings in the present study of a correlation between the increased expression of PTBR 
sites in vulnerable CA1 subfields of TLE patients with the presence of hippocampal 
sclerosis suggest that the Positron Emission Tomography (PET) ligand [11C]PK11195 may 
be useful in imaging the degree of hippocampal damage in TLE patients similar to that 
previously proposed for imaging of the extent of brain lesions in Wernicke’s 
encephalopathy (Leong et al., 1996) and multiple sclerosis (Banati et al., 2000). 
Other PET ligands such as [11C]flumazenil ([ 11C]FMZ) have been used extensively to 
evaluate the extent of neuronal loss in patients with refractory TLE. [11C]FMZ binds to the 
GABA-related central benzodiazepine receptor and can be used in vivo to detect 
remaining neurons in sclerotic hippocampi. In many cases, however, [11C]FMZ showed 
poor spatial correlation with neuronal cell loss and therefore has not been proven 
consistently helpful in localizing the epileptic foci (Koepp et al., 2000). Autoradiographic 
studies in experimental model of Wernicke’s encephalopathy revealed that increases in 
[3H]PK11195 binding sites paralleled the topographic distribution of neuronal cell loss 
and reactive gliosis more accurately than changes in the densities of [3H]FMZ binding 
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sites (Leong et al., 1996), suggesting that [11C]PK11195 represents a more reliable PET 
ligand to evaluate neuronal cell loss. Further studies are clearly warranted in order to 
evaluate this possibility. 
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